Business Context and Reporting Period
Company: Accuray Incorporated
Filing Type: Form 8-K (Current Report)
Date of Report: January 11, 2016
Event: Entry into a Material Definitive Agreement (Financing Agreement).
Key Financial Metrics and Debt Structure
This filing details a new debt facility rather than reporting operational financial results (revenue, profit, or cash flow) for a specific period.
- Facility Amount: $70 million term loan credit facility.
- Borrowers: Accuray Incorporated and its wholly-owned subsidiary, TomoTherapy Incorporated.
- Guarantor: Morphormics Inc. (wholly-owned subsidiary).
- Agent: Cerberus Business Finance, LLC.
- Interest Rate: Variable rate at the Company's option:
- LIBOR + 7.00% (LIBOR floor of 1.00%).
- Reference Rate + 4.75% (Reference Rate floor of 3.25%).
- Amortization: $875,000 payable quarterly (April, July, October, January), commencing April 1, 2016.
- Prepayment Premium: 2% if repaid within the first year; 1% if repaid within the second year.
- Collateral: First-priority liens on substantially all assets of the Loan Parties.
Material Changes and Purpose of Financing
The primary material change is the incurrence of new debt to manage existing obligations.
- Use of Proceeds: To repurchase and/or retire the Company's convertible notes maturing August 1, 2016.
- Maturity Date: The earlier of January 11, 2021, or the "Springing Maturity Date" (120 days prior to the maturity of the 2018 Convertible Notes on February 1, 2018), unless the Company segregates funds equal to the outstanding principal of the 2018 Convertible Notes.
Covenants, Risks, and Management Commentary
The Financing Agreement imposes significant financial and operational restrictions on the Company and its subsidiaries.
- Financial Covenants: The Company must maintain minimum Consolidated EBITDA and Fixed Charge Coverage Ratio, and maximum Secured and Total Leverage Ratios for each fiscal quarter.
- Operational Restrictions: Limits on incurring additional indebtedness, creating liens, paying dividends, selling assets, making investments, merging, or entering into affiliate transactions.
- Subsidiary Obligations: Any subsequently acquired or formed domestic subsidiary must guarantee the obligations and grant liens on its assets.
- Risks: Failure to meet covenants or payment obligations could trigger events of default. The filing does not provide specific guidance on future revenue or earnings.
Investor Verification Checklist
- Verify the outstanding principal amount of the convertible notes maturing August 1, 2016, to assess the immediate liquidity impact.
- Review the Company's current Consolidated EBITDA and Leverage Ratios to determine compliance with the new covenants.
- Confirm the status of the 2018 Convertible Notes to understand the potential "Springing Maturity Date" trigger.
- Examine the full text of the Financing Agreement (to be filed as an exhibit to the Form 10-Q for the quarter ended March 31, 2015) for detailed covenant definitions.